<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Mineralys Therapeutics, Inc. Common Stock — News on 6ix</title>
<link>https://6ix.com/company/mineralys-therapeutics-inc-common-stock</link>
<description>Latest news and press releases for Mineralys Therapeutics, Inc. Common Stock on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 29 Apr 2026 20:05:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/mineralys-therapeutics-inc-common-stock" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo68359a9c78dffbe2df1065da.webp</url>
<title>Mineralys Therapeutics, Inc. Common Stock</title>
<link>https://6ix.com/company/mineralys-therapeutics-inc-common-stock</link>
</image>
<item>
<title>Mineralys Therapeutics to Announce First Quarter 2026 Financial Results and Host Conference Call on Wednesday, May 6, 2026</title>
<link>https://6ix.com/company/mineralys-therapeutics-inc-common-stock/news/mineralys-therapeutics-to-announce-first-quarter-2026-financial-results-and-host-conference-call-on-wednesday-may-6-2026</link>
<guid isPermaLink="true">https://6ix.com/company/mineralys-therapeutics-inc-common-stock/news/mineralys-therapeutics-to-announce-first-quarter-2026-financial-results-and-host-conference-call-on-wednesday-may-6-2026</guid>
<pubDate>Wed, 29 Apr 2026 20:05:00 GMT</pubDate>
<description>RADNOR, Pa., April 29, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, announced it will report its financial results from the first quarter ended March 31, 2026, after the financial markets close on Wednesday, May 6, 2026. Wednesday, May 6th@ 4:</description>
</item>
<item>
<title>Mineralys Therapeutics Appoints Jeffrey A. Munsie as Chief Legal Officer</title>
<link>https://6ix.com/company/mineralys-therapeutics-inc-common-stock/news/mineralys-therapeutics-appoints-jeffrey-a-munsie-as-chief-legal-officer</link>
<guid isPermaLink="true">https://6ix.com/company/mineralys-therapeutics-inc-common-stock/news/mineralys-therapeutics-appoints-jeffrey-a-munsie-as-chief-legal-officer</guid>
<pubDate>Tue, 24 Mar 2026 04:00:00 GMT</pubDate>
<description>RADNOR, Pa., March 24, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to</description>
</item>
<item>
<title>Mineralys Therapeutics Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/mineralys-therapeutics-inc-common-stock/news/mineralys-therapeutics-reports-fourth-quarter-2025-financial-results-and-provides-corporate-update</link>
<guid isPermaLink="true">https://6ix.com/company/mineralys-therapeutics-inc-common-stock/news/mineralys-therapeutics-reports-fourth-quarter-2025-financial-results-and-provides-corporate-update</guid>
<pubDate>Thu, 12 Mar 2026 20:05:00 GMT</pubDate>
<description>– Announced FDA acceptance of NDA for lorundrostat in adults with hypertension; assigned PDUFA target date of December 22, 2026 – – Conference call today at 4:30 p.m. ET – RADNOR, Pa., March 12, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, tod</description>
</item>
<item>
<title>Mineralys Therapeutics Announces FDA Acceptance of NDA for Lorundrostat for Treatment of Adults with Hypertension and Topline Explore-OSA Trial Results</title>
<link>https://6ix.com/company/mineralys-therapeutics-inc-common-stock/news/mineralys-therapeutics-announces-fda-acceptance-of-nda-for-lorundrostat-for-treatment-of-adults-with-hypertension-and-topline-explore-osa-trial-results</link>
<guid isPermaLink="true">https://6ix.com/company/mineralys-therapeutics-inc-common-stock/news/mineralys-therapeutics-announces-fda-acceptance-of-nda-for-lorundrostat-for-treatment-of-adults-with-hypertension-and-topline-explore-osa-trial-results</guid>
<pubDate>Mon, 09 Mar 2026 04:00:00 GMT</pubDate>
<description>– The FDA assigned a PDUFA target action date of December 22, 2026 – – The NDA is based on positive data from a successful clinical program demonstrating</description>
</item>
<item>
<title>Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on Thursday, March 12, 2026</title>
<link>https://6ix.com/company/mineralys-therapeutics-inc-common-stock/news/mineralys-therapeutics-to-announce-fourth-quarter-and-full-year-2025-financial-results-and-host-conference-call-on-thursday-march-12-2026</link>
<guid isPermaLink="true">https://6ix.com/company/mineralys-therapeutics-inc-common-stock/news/mineralys-therapeutics-to-announce-fourth-quarter-and-full-year-2025-financial-results-and-host-conference-call-on-thursday-march-12-2026</guid>
<pubDate>Mon, 09 Mar 2026 04:00:00 GMT</pubDate>
<description>RADNOR, Pa., March 09, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to</description>
</item>
<item>
<title>Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)</title>
<link>https://6ix.com/company/mineralys-therapeutics-inc-common-stock/news/mineralys-therapeutics-reports-inducement-awards-000000935</link>
<guid isPermaLink="true">https://6ix.com/company/mineralys-therapeutics-inc-common-stock/news/mineralys-therapeutics-reports-inducement-awards-000000935</guid>
<pubDate>Thu, 12 Feb 2026 00:00:00 GMT</pubDate>
<description>RADNOR, Pa., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, announced today that on February 9, 2026, the Compensation Committee of Mineralys’ Board of Directors granted inducement stock option awards covering 33,504 shar</description>
</item>
<item>
<title>Mineralys Therapeutics Provides Corporate Update and Announces Participation in Upcoming LifeSci Partners Corporate Access Event in January 2026</title>
<link>https://6ix.com/company/mineralys-therapeutics-inc-common-stock/news/mineralys-therapeutics-provides-corporate-update-and-announces-participation-upcoming</link>
<guid isPermaLink="true">https://6ix.com/company/mineralys-therapeutics-inc-common-stock/news/mineralys-therapeutics-provides-corporate-update-and-announces-participation-upcoming</guid>
<pubDate>Tue, 06 Jan 2026 05:00:00 GMT</pubDate>
<description>RADNOR, Pa., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing</description>
</item>
<item>
<title>Mineralys Therapeutics’ Phase 3 Launch-HTN Trial of Lorundrostat Recognized in Inaugural Journal of the American Medical Association (JAMA) “Research of the Year” Roundup</title>
<link>https://6ix.com/company/mineralys-therapeutics-inc-common-stock/news/mineralys-therapeutics-phase-3-launch-htn-trial-lorundrostat-recognized-inaugural</link>
<guid isPermaLink="true">https://6ix.com/company/mineralys-therapeutics-inc-common-stock/news/mineralys-therapeutics-phase-3-launch-htn-trial-lorundrostat-recognized-inaugural</guid>
<pubDate>Fri, 12 Dec 2025 05:00:00 GMT</pubDate>
<description>– Launch-HTN, the largest trial of an aldosterone synthase inhibitor conducted among participants with uncontrolled or treatment-resistant hypertension, was</description>
</item>
<item>
<title>Mineralys Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)</title>
<link>https://6ix.com/company/mineralys-therapeutics-inc-common-stock/news/mineralys-therapeutics-reports-inducement-award-under-nasdaq-listing-rule-5635c4-2025</link>
<guid isPermaLink="true">https://6ix.com/company/mineralys-therapeutics-inc-common-stock/news/mineralys-therapeutics-reports-inducement-award-under-nasdaq-listing-rule-5635c4-2025</guid>
<pubDate>Wed, 26 Nov 2025 05:00:00 GMT</pubDate>
<description>RADNOR, Pa., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing</description>
</item>
<item>
<title>Mineralys Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/mineralys-therapeutics-inc-common-stock/news/mineralys-therapeutics-reports-third-quarter-2025-financial-results-and-provides</link>
<guid isPermaLink="true">https://6ix.com/company/mineralys-therapeutics-inc-common-stock/news/mineralys-therapeutics-reports-third-quarter-2025-financial-results-and-provides</guid>
<pubDate>Mon, 10 Nov 2025 05:00:00 GMT</pubDate>
<description>– Submission of New Drug Application (NDA) for lorundrostat planned for late-2025/Q1 2026 – – Completed enrollment in Explore-OSA trial; topline results</description>
</item>
<item>
<title>Data for Lorundrostat in Chronic Kidney Disease and Hypertension Presented at American Society of Nephrology (ASN) Kidney Week 2025</title>
<link>https://6ix.com/company/mineralys-therapeutics-inc-common-stock/news/data-lorundrostat-chronic-kidney-disease-and-hypertension-presented-american-society</link>
<guid isPermaLink="true">https://6ix.com/company/mineralys-therapeutics-inc-common-stock/news/data-lorundrostat-chronic-kidney-disease-and-hypertension-presented-american-society</guid>
<pubDate>Fri, 07 Nov 2025 05:00:00 GMT</pubDate>
<description>– Late-breaking presentation of Explore-CKD trial at ASN Kidney Week – – Pivotal Phase 3 Launch-HTN trial featured in the “Best of JAMA and NEJM” session -</description>
</item>
<item>
<title>Mineralys Therapeutics to Participate in Upcoming Investor Conferences</title>
<link>https://6ix.com/company/mineralys-therapeutics-inc-common-stock/news/mineralys-therapeutics-participate-upcoming-investor-conferences-2025-11-05</link>
<guid isPermaLink="true">https://6ix.com/company/mineralys-therapeutics-inc-common-stock/news/mineralys-therapeutics-participate-upcoming-investor-conferences-2025-11-05</guid>
<pubDate>Wed, 05 Nov 2025 05:00:00 GMT</pubDate>
<description>RADNOR, Pa., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing</description>
</item>
<item>
<title>Mineralys Therapeutics to Announce Third Quarter 2025 Financial Results and Host Conference Call on Monday, November 10, 2025</title>
<link>https://6ix.com/company/mineralys-therapeutics-inc-common-stock/news/mineralys-therapeutics-announce-third-quarter-2025-financial-results-and-host</link>
<guid isPermaLink="true">https://6ix.com/company/mineralys-therapeutics-inc-common-stock/news/mineralys-therapeutics-announce-third-quarter-2025-financial-results-and-host</guid>
<pubDate>Mon, 03 Nov 2025 05:00:00 GMT</pubDate>
<description>RADNOR, Pa., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing</description>
</item>
<item>
<title>Mineralys Therapeutics Announces Late-Breaking Presentation of Phase 2 Explore-CKD Trial of Lorundrostat at American Society of Nephrology (ASN) Kidney Week 2025</title>
<link>https://6ix.com/company/mineralys-therapeutics-inc-common-stock/news/mineralys-therapeutics-announces-late-breaking-presentation-phase-2-explore-ckd-trial</link>
<guid isPermaLink="true">https://6ix.com/company/mineralys-therapeutics-inc-common-stock/news/mineralys-therapeutics-announces-late-breaking-presentation-phase-2-explore-ckd-trial</guid>
<pubDate>Tue, 21 Oct 2025 04:00:00 GMT</pubDate>
<description>~ Late-breaking Phase 2 trial data evaluating the safety and efficacy of 25 mg of lorundrostat in participants with hypertension and comorbid CKD to be</description>
</item>
<item>
<title>Mineralys Therapeutics Completes Enrollment in Phase 2 EXPLORE-OSA Trial of Lorundrostat in Obstructive Sleep Apnea and Hypertension</title>
<link>https://6ix.com/company/mineralys-therapeutics-inc-common-stock/news/mineralys-therapeutics-completes-enrollment-phase-2-explore-osa-trial-lorundrostat</link>
<guid isPermaLink="true">https://6ix.com/company/mineralys-therapeutics-inc-common-stock/news/mineralys-therapeutics-completes-enrollment-phase-2-explore-osa-trial-lorundrostat</guid>
<pubDate>Tue, 30 Sep 2025 04:00:00 GMT</pubDate>
<description>~ Topline results from the EXPLORE-OSA trial are anticipated in 1Q 2026 ~ RADNOR, Pa., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc.</description>
</item>
<item>
<title>Mineralys Therapeutics Presents Subgroup Analyses of Phase 3 Launch-HTN Trial Demonstrating Efficacy and Safety of Lorundrostat in Hypertension Participants with High Unmet Medical Need</title>
<link>https://6ix.com/company/mineralys-therapeutics-inc-common-stock/news/mineralys-therapeutics-presents-subgroup-analyses-130000314</link>
<guid isPermaLink="true">https://6ix.com/company/mineralys-therapeutics-inc-common-stock/news/mineralys-therapeutics-presents-subgroup-analyses-130000314</guid>
<pubDate>Fri, 05 Sep 2025 13:00:00 GMT</pubDate>
<description>~Pivotal Launch-HTN trial of novel aldosterone synthase inhibitor lorundrostat enrolled a diverse range of participants with uncontrolled or resistant hypertension~ ~Subgroups - including Black or African American adults, older adults, women, and participants with comorbid obesity – face heightened risk of poor cardiovascular outcomes and represent high unmet need~ ~Lorundrostat demonstrated significant and clinically meaningful blood pressure reductions across all participant subgroups, with a</description>
</item>
<item>
<title>Mineralys Therapeutics Presents Subgroup Analyses of Phase 3 Launch-HTN Trial Demonstrating Efficacy and Safety of Lorundrostat in Hypertension Participants with High Unmet Medical Need </title>
<link>https://6ix.com/company/mineralys-therapeutics-inc-common-stock/news/mineralys-therapeutics-presents-subgroup-analyses-phase-3-launch-htn-trial</link>
<guid isPermaLink="true">https://6ix.com/company/mineralys-therapeutics-inc-common-stock/news/mineralys-therapeutics-presents-subgroup-analyses-phase-3-launch-htn-trial</guid>
<pubDate>Fri, 05 Sep 2025 04:00:00 GMT</pubDate>
<description>~Pivotal Launch-HTN trial of novel aldosterone synthase inhibitor lorundrostat enrolled a diverse range of participants with uncontrolled or resistant</description>
</item>
<item>
<title>Mineralys Therapeutics Announces Closing of Upsized $287.5 Million Underwritten Public Offering of Common Stock Including Full Exercise of Underwriters’ Option to Purchase Additional Shares</title>
<link>https://6ix.com/company/mineralys-therapeutics-inc-common-stock/news/mineralys-therapeutics-announces-closing-upsized-2875-million-underwritten-public</link>
<guid isPermaLink="true">https://6ix.com/company/mineralys-therapeutics-inc-common-stock/news/mineralys-therapeutics-announces-closing-upsized-2875-million-underwritten-public</guid>
<pubDate>Thu, 04 Sep 2025 04:00:00 GMT</pubDate>
<description>RADNOR, Pa., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing</description>
</item>
<item>
<title>Mineralys Therapeutics Announces Pricing of Upsized $250.0 Million Underwritten Public Offering of Common Stock</title>
<link>https://6ix.com/company/mineralys-therapeutics-inc-common-stock/news/mineralys-therapeutics-announces-pricing-upsized-2500-million-underwritten-public</link>
<guid isPermaLink="true">https://6ix.com/company/mineralys-therapeutics-inc-common-stock/news/mineralys-therapeutics-announces-pricing-upsized-2500-million-underwritten-public</guid>
<pubDate>Tue, 02 Sep 2025 04:00:00 GMT</pubDate>
<description>RADNOR, Pa., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing</description>
</item>
<item>
<title>Mineralys Therapeutics Announces Proposed Public Offering of Common Stock</title>
<link>https://6ix.com/company/mineralys-therapeutics-inc-common-stock/news/mineralys-therapeutics-announces-proposed-public-offering-common-stock-2025-09-02</link>
<guid isPermaLink="true">https://6ix.com/company/mineralys-therapeutics-inc-common-stock/news/mineralys-therapeutics-announces-proposed-public-offering-common-stock-2025-09-02</guid>
<pubDate>Tue, 02 Sep 2025 04:00:00 GMT</pubDate>
<description>RADNOR, Pa., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing</description>
</item>
</channel>
</rss>